

Lead Product(s) : Recoflavone
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DA-6034 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Gastritis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 19, 2013
Lead Product(s) : Recoflavone
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Recoflavone
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase II Study of DA-6034 Eye Drops in Dry Eye Syndrome
Details : DA-6034 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dry Eye Syndromes.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 22, 2012
Lead Product(s) : Recoflavone
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Recoflavone
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase I Study to Evaluate the Tolerability of Eye Drop DA-6034 in Healthy Volunteers
Details : DA-6034 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Dry Eye Syndromes.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 15, 2010
Lead Product(s) : Recoflavone
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
